Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

Associate Administrator
Chief Medical Officer
Health Resources and Services Administration
Rockville, MD

Topics of Professional Interest:
  • Adherence to treatment
  • Treatment of substance abusers with HIV
  • Prevention strategies for HIV-seropositive individuals
Current Professional Summary:

Dr Cheever is the Deputy Director and Chief Medical Officer of the HIV/AIDS Bureau at HRSA. She provides clinical policy and administrative oversight of the Ryan White CARE Act and the international portfolio in the Bureau. She is a part-time faculty member at Johns Hopkins University School of Medicine and in this capacity provides primary and specialty care on a weekly basis to HIV-seropositive patients. Previously, Dr Cheever was the National Director of the AIDS Education and Training Centers program, ran a statewide HIV care program, and served as the medical director of a methadone-based substance abuse treatment center.

Committees and Organizations:
  • Member, Department of Health and Human Services Adult and Adolescent Antiretroviral Guidelines Panel
  • Member, Infectious Diseases Society of America
Honors and Awards:
  • HRSA Administrator's Special Citation for exemplary commitment and leadership in providing HIV/AIDS clinical education and training for the nation's health care providers
  • Certificate of Special Congressional Recognition, US Congress, for service to the HIV/AIDS patient community of Harford County, MD
  • Brown University, BA, Biology (1987)
  • Brown University, MD, Medicine (1990)
  • University of California San Francisco, Internal Medicine Internship and Residency (1990-1993)
  • Johns Hopkins University, Infectious Diseases Fellow (1993-1997)
Selected Publications:
  1. Gordon CM, Stall R, Cheever LW. Prevention interventions in persons living with HIV/AIDS: Challenges, progress, and research priorities. J Acquir Immune Defic Syndr, in press.
  2. Lucas GM, Wu AW, Cheever LW. Adherence to antiretroviral therapy: an update of current concepts. Current HIV Reports, in press.
  3. Gordon CM, Forsyth AD, Stall R, Cheever LW. Prevention interventions in persons living with HIV/AIDS: State of the science and future directions. AIDS Educ and Prev, in press.
  4. Kresina TF, Flexner CW, Sinclair J, Correia MA, Stapleton JT, Adeniyi-Jones S, Cargill V, and Cheever LW. Alcohol use and HIV pharmacology. AIDS Research and Human Retroviruses. 2002;46:91-92.
  5. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251-259.
  6. Flexner CW, Cargill VA, Sinclair J, Kresina TF, Cheever L. Alcohol use can result in enhanced drug metabolism in HIV pharmacotherapy. AIDS Patient Care STDS. 2001;15:57-58.
  7. Cheever LW, Wu AW. Medication Adherence Among HIV-Infected Patients: Understanding the Complex Behavior of Patients Taking This Complex Therapy. Curr Infect Dis Rep. 1999;1:401-407.
  8. Moore RD, Cheever LW, Keruly JC, Chaisson RE. Lack of sex difference in CD4 to HIV-1 RNA viral load ratio. Lancet. 1999;353:463-464.


Webcasts of the The Clinical Pathway Track of the 2016 National Ryan White Conference on HIV Care & Treatment

15th Ryan White HIV/AIDS AETC Program Clinical CARE Conference: Moving Forward with CARE: Focusing on Passion, Purpose, and Excellence

14th Annual Clinical Conference for the Ryan White HIV/AIDS Program